Page last updated: 2024-12-05

ethyl laurate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethyl laurate is an ester produced from the reaction of lauric acid and ethanol. It is a colorless, odorless liquid that is insoluble in water but soluble in organic solvents. It is found in coconut oil and palm kernel oil, and is also produced synthetically. Ethyl laurate is used in cosmetics and personal care products as an emollient and skin conditioning agent. It is also used in food as a flavoring agent and as a component of some types of edible oils. Ethyl laurate is being studied for its potential health benefits, such as its antioxidant and anti-inflammatory properties. Its biocompatibility and low toxicity make it a promising candidate for various applications in medicine, food, and cosmetics.'

ethyl laurate : A fatty acid ethyl ester of lauric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7800
CHEMBL ID3187842
CHEBI ID87427
SCHEMBL ID8538
MeSH IDM0051018

Synonyms (69)

Synonym
dodecanoic acid, ethyl ester
ethyl laurate (natural)
ai3-00645
nsc 83467
fema no. 2441
einecs 203-386-0
106-33-2
nsc-8912
nsc8912
lauric acid, ethyl ester
ethyl dodecanoate
ethyl dodecylate
ethyl laurinate
ethyl laurate
nsc83467
nsc-83467
inchi=1/c14h28o2/c1-3-5-6-7-8-9-10-11-12-13-14(15)16-4-2/h3-13h2,1-2h
dodecanoic acid,ethyl ester
ethyl laurate, >=98%, fcc, fg
ethyl laurate, natural, >=98%, fcc, fg
NCIOPEN2_004797
ethyl dodecanoate, >=98.0% (gc)
lauric acid ethyl ester
L0013
NCGC00248234-01
we(2:0/12:0)
LMFA07010464
NCGC00254870-01
dtxcid2027044
tox21_300967
cas-106-33-2
dtxsid4047044 ,
f389d4md5k ,
unii-f389d4md5k
FT-0625573
AKOS009157278
ethyl n-dodecanoate
dodecanoic acid ethyl ester
ethyl laurate [mi]
ethyl laurate [inci]
ethyl laurate [fhfi]
ethyl laurate [usp-rs]
ethyl laurate [fcc]
SCHEMBL8538
ethyl ester of dodecanoic acid
ethyl n-dodecanote
CHEMBL3187842
chebi:87427 ,
mfcd00015065
F8889-6672
J-001577
ethyl laurate, united states pharmacopeia (usp) reference standard
ethyl laurate, analytical standard
ethyl dodecanoate, vetec(tm) reagent grade, 98%
dodecanoic acid-ethyl ester
ethyl laurate; ethyl dodecanoate; dodecanoic acid ethyl ester
ethyllaurate
ethyl ester dodecanoic acid
fema 2441
lauric acid, ethyl ester (8ci)
SY037739
BS-14294
Q18023029
D70267
A934209
ethyl laurate(ethyl dodecanoate)
CS-W010400
EN300-1265982
HY-W009684

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" At 2 mg/kg dose, the maximum drug plasma concentration was arrived within 2-3 min, and the bioavailability (0-2 h) after nasal spray compared with intravenous injection was about 50%."( Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam.
Kim, KH; Li, L; Nandi, I, 2002
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
fatty acid ethyl esterA fatty acid ester that is the carboxylic ester obtained by the formal condensation of a fatty acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoid X nuclear receptor alphaHomo sapiens (human)Potency41.26820.000817.505159.3239AID1159527; AID1159531
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.87240.001024.504861.6448AID743215
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1659751Agonist activity at TRPA1 (unknown origin) at 1000 uM relative to AITC2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Identification of a new class of non-electrophilic TRPA1 agonists by a structure-based virtual screening approach.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's2 (15.38)18.2507
2000's1 (7.69)29.6817
2010's5 (38.46)24.3611
2020's4 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.42 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index47.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]